• 8:30 - 18:00 M-T / 8.30 - 15.00 F

HC016 Acute Lung Injury

The HC016 platform is a treatment of acute lung injury, based on mesenchymal stem cells derived from adipose tissue (ASC), improved with proprietary Histocell technology.

Development stage

"In vivo" Poc study finished with promising results.

"In vivo" Safety regulatory study finished with good safety profile.

Phase I/II clinical trial for Acute Respiratory Distress Syndrome (ARDS) was approved by the Spanish Agency of Medicines and Medical Devices in December 2019.

Phase I: Dose escalating Phase I study in 6 patients with moderate to severe ARDS inluded in 2 sequential cohorts.

Phase II: Randomised, controlled, double-blind. 20 patients with moderate to severe ARDS divided into 2 groups (treated and control).

Recruiting starts: Q2 2020.


Histocell, S.L.
Parque Tecnológico 801A, 2º
48160 Derio
Bizkaia - Spain

+34 94 656 7900

Our mission

We develop new healthcare products and cell therapy drugs to improve people's quality of life.

Copyright © Histocell